C5 (UK) will be
holding its 2nd Annual Pharma & Biotech Patent Litigation conference on
January 27-28, 2010 in Amsterdam, Netherlands.  The conference will provide strategic guidance regarding the
following issues:

• Is the
Enforcement Directive an effective tool for brand name pharma in enforcing
patents:  Analysis of post
Directive case law;
• The latest
European Patent Office decisions and their implications:  Hear directly from the EPO's Legal
Member to the Boards of Appeal;
• SPCs and
paediatric regulation:  Recent
decisions and varying application requirements across Europe;
• Pharma Sector
Inquiry Final Report:  What lessons
can both innovators and generics companies draw?
• European
Standards on sufficiency of description post Lundbeck and Novartis v
Johnson & Johnson; and
• Enforcing IP
rights in China, India, Russia and Israel:  Local practitioners' guide to the facilitative provisions
and stumbling blocks.

In particular, C5
faculty will offer presentations on the following topics:

• Highlights from
pharma and biotech patent litigation in 2009 and trends for the future;
• The Generics (UK) v Lundbeck case and
subsequent conflicting decisions in the Netherlands and Germany:  What is the European position on
sufficiency today?
• Post-enforcement
Directive case law across Europe: 
New opportunities for effective enforcement of IP rights by innovators?
• In discussion
with the European Patent Office: 
Update on recent decisions;
• SPC
litigation:  Recent case law and
varying requirements for SPCs across Europe;
• Critical analysis
of key issues and recent case law involving pediatric extensions;
• Pharma and
biotech infringement litigation in China, India, Russia, and Israel;
• Special
address:  How have recent landmark
decisions impacted the U.S. litigation landscape? — Judge Randall Rader,
United States Court of Appeals for the Federal Circuit;
• Pharma sector
final report:  What are the
implications for industry?
• Settlement
agreements post pharma Sector Inquiry: 
What can and cannot be done?
• Beyond the
injunction:  The battle for damages
in pharma patent litigation;
• Using experiments
in pharma and biotech patent litigation: 
Key legal and practical considerations; and
• Strategies and
best practice for conducting and managing complex multi-jurisdictional
litigation.

An additional
post-conference master class, entitled "Winning Strategies for Enforcing
Your Life Sciences Patents in China and India," will be offered on January
29, 2010.  This master class will
examine patent enforcement in two jurisdictions — China and India — that, for
the European pharma and biotech industry, are crucially important given the
strong presence of local generics companies.

A complete brochure
for this conference, including an agenda, list of speakers, and registration
form can be downloaded here.

The registration
fee for the conference is £1399 ($2,044.67), for the conference plus master
class £1798 ($2,627.81), and for the master class alone £499 ($729.30).  Those interested in registering for the
conference can do so here, by
calling +44 (0) 20 7878 6888, or by faxing a registration form to +44 (0) 20
7878 6896.